SNDX
$23.77
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Recent News
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge?
If you are wondering whether Syndax Pharmaceuticals at around US$23.77 is still offering value after a strong run, the next sections will walk through what the current price may be implying. The stock has returned 16.1% over the last 30 days and 88.5% over the last year, while year to date it is up 11.6% and the past week shows a 1.6% decline. Recent coverage has focused on Syndax Pharmaceuticals' share price strength over the past year and how that compares with its longer term 3 year and 5...
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success. uniQure: ... uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs
Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant […]